---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-045867"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-10-06T12:30:20+00:00"
generated_at: "2026-10-12T16:32:01.039683+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bioAffinity reports CyPath Lung sales up over 100% through Q3 2026

## Summary
- CyPath Lung sales rose more than 100% through Q3 2026 versus 2025, with 1,620 tests delivered compared to 775 in Q3 2025.
- Ordering physicians increased 89% in Q3 2026 versus Q3 2025; prior prescribers' sales volume rose 48% year-over-year.
- CEO Maria Zannes cited a new distribution agreement with Veteran-Owned AvMEDICAL to broaden reach in government healthcare, including the Department of Veterans Affairs.
- CyPath Lung reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in high-risk patients with nodules under 20 mm.

## SEC filing metadata
- accession: 0001493152-26-045867
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-10-06T12:30:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226045867/0001493152-26-045867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226045867/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-045867
- JSON: https://secwatch.observer/filing/0001493152-26-045867.json
- Plain text: https://secwatch.observer/filing/0001493152-26-045867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.